Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An artificial ...
Survival impact of initial local therapy selection for men under 60 with high risk prostate cancer. Prostate cancer (PCa) in 696 hypogonadal men with and without long-term testosterone therapy (TTh): ...
Combining PSA density with prostate MRI findings improves the predictive performance of PI-RADS in men without a prior prostate cancer diagnosis. Combining PSA density (PSAD) with prostate magnetic ...
Upgrade and downgrade rates from targeted biopsy to radical prostatectomy were not significantly different between patients whose MRI examinations were clinically interpreted using PI-RADS Version ...
PI-RADS version 2.1 demonstrated improved detection of clinically significant prostate cancer in the transition zone. For detecting clinically significant prostate cancer (csPCa), prostate imaging ...
Prostate specific antigen testing as disease surveillance and monitoring five years after definitive therapy for localized prostate cancer. Relative risk of HTN and major cardiovascular events ...
Adding baseline MRI to conventional prostate cancer risk stratification could improve prognostic accuracy, potentially affecting active surveillance and treatment decisions for some patients, ...
MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results